应变波弹性成像评估局部晚期乳腺癌新辅助化疗疗效
本研究纳入86例局部晚期乳腺癌患者,在每周期新辅助化疗前及术前用应变波弹性成像由两名独立观察者扫描患侧乳腺,记录尺寸比与应变比变化并与临床和病理反应对比。应变比在首周期化疗后即显示高敏感度(97.7%)和中等特异度(68.7%);尺寸比在第二、三周期后显示中等敏感度与特异度。作者认为应变比是治疗反应的最早预测指标。
要点
- 应变比在首周期新辅助化疗后即达97.7%敏感度、68.7%特异度,为最早预测指标。
- 尺寸比在第二周期后敏感度83.3%、特异度80%,第三周期后敏感度77.8%、特异度100%。
- 弹性成像系列扫描可在新辅助化疗早期预测治疗反应,可能为调整治疗方案提供窗口。
核心结论
- 应变比是局部晚期乳腺癌患者治疗反应的最早预测指标;弹性成像系列扫描有潜力在新辅助化疗早期预测治疗反应,可能对乳腺癌患者管理至关重要。
研究设计与样本
- 经机构审查委员会批准的研究,纳入86例局部晚期乳腺癌患者,接受新辅助化疗的女性在每周期化疗前及术前由两名独立观察者行应变波弹性成像扫描,记录弹性成像参数(尺寸比、应变比)变化,并与乳房切除术后评估的临床和病理肿瘤反应对比。
关键影像表现/征象
- 应变比参数在首周期新辅助化疗后即显示高敏感度和中等特异度用于判断治疗反应。
- 尺寸比参数在第二和第三周期新辅助化疗后显示中等敏感度和特异度用于检测治疗反应。
诊断标准与关键数值
- 应变比判断治疗反应:首周期新辅助化疗后敏感度97.7%、特异度68.7%。
- 尺寸比判断治疗反应:第二周期新辅助化疗后敏感度83.3%、特异度80%。
- 尺寸比判断治疗反应:第三周期新辅助化疗后敏感度77.8%、特异度100%。
临床应用与阅片要点
- 应变比可在首周期新辅助化疗后即用于评估治疗反应,敏感度97.7%、特异度68.7%。
- 尺寸比在第二周期后(敏感度83.3%、特异度80%)和第三周期后(敏感度77.8%、特异度100%)用于检测治疗反应。
- 作者认为弹性成像系列扫描有潜力在新辅助化疗早期预测治疗反应,可能为改变治疗方案提供最佳窗口。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The study was conducted to study the role of strain wave elastography in evaluating the response to neo-adjuvant chemotherapy (NACT) in patients with locally advanced breast cancer (LABC).
METHODS: In this Institutional review board approved study, 86 patients of LABC were investigated with strain wave elastography. Females receiving NACT had the affected breast scanned by strain wave elastography before each cycle of chemotherapy and immediately before surgery by two independent observers. Changes in elastographic parameters (size ratio, strain ratio) were documented and then compared to clinical and pathologic tumor response as evaluated after mastectomy.
RESULTS: Elastographic strain ratio parameters demonstrated high sensitivity and moderate specificity for determining response even after the first cycle of neo-adjuvant chemotherapy [97.7% sensitivity (Sn), 68.7% specificity (Sp)]. Elastographic size ratio parameters showed moderate sensitivity and specificity for response detection after second and third cycle of neo-adjuvant chemotherapy (Sn, Sp: after second cycle of NACT Sn 83.3% Sp 80%; after third cycle of NACT Sn 77.8% Sp 100%).
CONCLUSION: Strain ratio is the earliest predictor of treatment response in patients of LABC. Serial imaging with elastography has the potential to predict treatment response early during the course of NACT, which may prove vital in management of patients with breast cancer.
ADVANCES IN KNOWLEDGE: Strain wave elastography is a powerful tool to predict chemoresponse early during the course of management, thereby providing an optimal window to change treatment protocols.
引用
- Katyan A, Mittal MK, Mani C, et al. Strain wave elastography in response assessment to neo-adjuvant chemotherapy in patients with locally advanced breast cancer. Br J Radiol. 2019. PMID: 31045431. doi:10.1259/bjr.20180515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。